Linzagolix manufacturers
- Linzagolix
-
- $0.00 / 10mg
-
2025-05-27
- CAS:935283-04-8
- Min. Order: 10mg
- Purity: 98
- Supply Ability: 10000000
- Linzagolix
-
- $0.00 / 1g
-
2024-11-19
- CAS:935283-04-8
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 100kg
|
| | Linzagolix Basic information |
| Product Name: | Linzagolix | | Synonyms: | Linzagolix;Thieno[3,4-d]pyrimidine-5-carboxylic acid, 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-1,2,3,4-tetrahydro-2,4-dioxo-;OBE 2109;OBE2109;OBE-2109;KLH 2109,endometriosis,KLH-2109,GnRH Receptor,Gonadotropin releasing hormone receptor,inhibit,uterine fibroids,KLH2109,Linzagolix,GNRHR,adenomyosis,OBE 2109,Inhibitor,OBE-2109,OBE2109;3-[5-[(2,3-Difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-1,2,3,4-tetrahydro-2,4-dioxothieno[3,4-d]pyrimidine-5-carboxylic acid;3-(5-((2,3-difluoro-6-methoxybenzyl)oxy)-2-fluoro-4-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid | | CAS: | 935283-04-8 | | MF: | C22H15F3N2O7S | | MW: | 508.42 | | EINECS: | | | Product Categories: | | | Mol File: | 935283-04-8.mol |  |
| | Linzagolix Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (245.86 mM; Need ultrasonic) | | form | Solid | | color | White to light brown |
| | Linzagolix Usage And Synthesis |
| Uses | Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for uterine fibroids, endometriosis, adenomyosis research[1][2][3]. | | in vivo | Linzagolix (50 mg/kg) reduces cyst volume in a rat model of endometriosis[1].
Lindagolix reduces serum luteinizing hormone and testosterone levels in male rats and dogs with normal or BPH models[2]. | Animal Model: | Endometriosis model rat[1] | | Dosage: | 50 mg/kg | | Administration: | | | Result: | Reduced cyst volume. |
| | References | [1] Motohiro Tezuka, et al. Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats. Clin Exp Pharmacol Physiol. 2023 Jul;50(7):610-617. DOI:10.1111/1440-1681.13778
[2] Motohiro Tezuka, et al. Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models. Clin Exp Pharmacol Physiol. 2023 Nov;50(11):914-923. DOI:10.1111/1440-1681.13817
[3] Susan Dababou, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Sep;30(9):903-911. DOI:10.1080/13543784.2021.1957830 |
| | Linzagolix Preparation Products And Raw materials |
| Raw materials | Benzene, 2-(chloromethyl)-3,4-difluoro-1-methoxy--->Benzenamine, 5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxy--->Benzene, 1,2-difluoro-3-[(4-fluoro-2-methoxyphenoxy)methyl]-4-methoxy--->Benzene, 1,2-difluoro-3-[(4-fluoro-2-methoxy-5-nitrophenoxy)methyl]-4-methoxy--->2,3-DIFLUORO-6-METHOXYBENZALDEHYDE-->2,3-DIFLUORO-6-METHOXYBENZYL ALCOHOL |
|